S. Olofsson

Low RBM3 Protein Expression Correlates with Clinical Stage, Prognostic Classification and Increased Risk of Treatment Failure in Testicular Non-Seminomatous Germ Cell Cancer

M. Uhlén, K. Jirström, M. Jerkeman, 2015, PloS one.

Low RBM3 Protein Expression Correlates with Clinical Stage, Prognostic Classification and Increased Risk of Treatment Failure in Testicular Non-Seminomatous Germ Cell Cancer

M. Uhlén, K. Jirström, M. Jerkeman, 2015, PloS one.

Population-based study of treatment guided by tumor marker decline in patients with metastatic nonseminomatous germ cell tumor: a report from the Swedish-Norwegian Testicular Cancer Group.

R. Wahlqvist, O. Ståhl, M. Jerkeman, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Individualized intensification of treatment based on tumor marker decline in metastatic nonseminomatous germ cell testicular cancer (NSGCT): A report from the Swedish Norwegian Testicular Cancer Group, SWENOTECA.

R. Wahlqvist, M. Jerkeman, O. Dahl, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Testicular cancer – response adapted treatment, prognostic markers and survivorship issues

S. Olofsson, 2015 .

Translational study reveals a two-faced role of RBM3 in pancreatic cancer and suggests its potential value as a biomarker for improved patient stratification

M. Uhlén, A. Mardinoğlu, K. Jirström, 2017, Oncotarget.

1587PLOW RBM3 PROTEIN EXPRESSION CORRELATES WITH CLINICAL STAGE, PROGNOSTIC INDEX AND INCREASED RISK OF TREATMENT FAILURE IN TESTICULAR NON-SEMINOMATOUS GERM CELL CANCER.

M. Uhlén, K. Jirström, J. Eberhard, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.